Clinical Trial Update: Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

View source ↗

Summary

A clinical trial update indicates Fibroscan is being used to evaluate immunotherapy response in hepatocellular carcinoma and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Tanta University | Conditions: Hepato Cellular Carcinoma (HCC) | Status: RECRUITING